Diffusa symtom hos unga kvinnor kan tyda på venös tromboembolism. Viktigt att aktivt fråga om användning av kombinerad hormonell antikonception
Sammanfattning
Anually more than 100 women in Sweden will experience a venous thrombolic event (VTE) whilst using combined hormonal contraception (CHC) and a small number of these women will die as a result of the VTE. Cases of VTE where a woman has had a VTE whilst using CHC are reported to the National Drug Insurance Agency. An assessment of applications for compensation to the National Drug Insurance Agency in women who had experienced VTE whislst using CHC indicated that information on the use of CHC was noted at an all too late stage and the diagnosis of a VTE was also made very late. However, the assessment also indicated that CHC was most often prescribed according to current guidelines and few women with potential contraindications were prescribed CHC. The cases illustrated the importance of actively questioning the woman with regard to the use of CHC should she seek help for symptoms that could possibly indicate a VTE. The cases also indicate that if a woman seeks help for such symptoms and she is using CHC then it is imperative to exclude a diagnosis of VTE.